AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
20 Septiembre 2023 - 4:02PM
Business Wire
AbCellera (Nasdaq: ABCL) announced today that it has expanded
its existing multi-target collaboration with Regeneron (Nasdaq:
REGN) to discover therapeutic antibodies for up to eight targets
selected by Regeneron, increased from the original four.
“Having successfully delivered on two challenging discovery
campaigns under the original agreement, we are excited to expand
the scope of our collaboration with Regeneron to include up to four
additional targets,” said Carl Hansen, Ph.D., founder and CEO of
AbCellera. “We look forward to using our antibody discovery and
development engine to bolster Regeneron’s preclinical portfolio and
help identify promising candidates for their programs.”
The collaboration, which began in March 2020, leverages
AbCellera’s antibody discovery engine and Regeneron’s VelocImmune®
mice to identify novel therapeutic antibodies. AbCellera has
initiated programs for all four of the original targets, with
Regeneron exercising its rights to advance antibody candidates into
further preclinical development for the two programs that have been
completed.
Under the terms of the agreement, Regeneron has the right to
develop and commercialize therapeutic antibodies resulting from the
collaboration. AbCellera receives research payments and is eligible
to receive downstream clinical and regulatory milestone payments
and royalties on net sales of products.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230915605101/en/
Inquiries: Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
AbCellera Biologics (NASDAQ:ABCL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024